Developing a dual VEGF/PDL1 inhibitor based on high-affinity scFv heterodimers as an anti-cancer therapeutic strategy

Cancer progression is enhanced by the interaction of programmed death-ligand 1 (PDL1), which is associated with inhibition of the immune response against tumors, and vascular endothelial growth factor (VEGF), which inhibits immune cell activity while inducing angiogenesis and proliferation of cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Tzuri, Noam, Yegodayev, Ksenia M., Novoplansky, Ofra, Elkabets, Moshe, Aharoni, Amir, Papo, Niv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366146/
https://www.ncbi.nlm.nih.gov/pubmed/37488176
http://dx.doi.org/10.1038/s41598-023-39076-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366146/
https://www.ncbi.nlm.nih.gov/pubmed/37488176
http://dx.doi.org/10.1038/s41598-023-39076-8

Ejemplares similares